← Browse by Condition
Medical Condition
refractory diffuse large b cell lymphoma
Total Trials
5
Recruiting Now
5
Trial Phases
Phase 2, Phase 1
NCT07042438 Phase 2
Recruiting
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
Enrollment
56 pts
Location
United States
Sponsor
City of Hope Medical Center
NCT06458439 Phase 2
Recruiting
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Enrollment
31 pts
Location
United States
Sponsor
Abramson Cancer Center at Penn...
NCT05077527 Phase 1
Recruiting
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Enrollment
20 pts
Location
United States
Sponsor
AIDS Malignancy Consortium
NCT04920617 Phase 2
Recruiting
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Enrollment
102 pts
Location
United States, Austr...
Sponsor
ImmunoVaccine Technologies, In...
NCT06905509 Phase 2
Recruiting
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Enrollment
25 pts
Location
United States
Sponsor
Joseph Tuscano